Repligen CFO granted options and RSUs

Repligen Corporation CFO Jason K. Garland reported equity compensation awards consisting of stock options and restricted stock units.

Rhea-AI Filing Summary

Repligen Corporation CFO Jason K. Garland reported equity compensation awards consisting of stock options and restricted stock units. He received 8,315 stock options with an exercise price of $141.91 per share, expiring on March 5, 2036, which vest in three equal annual installments on March 5, 2027, March 5, 2028, and March 5, 2029. He was also granted 7,751 restricted stock units, vesting in equal annual installments over three years beginning on the first anniversary of the grant date, each unit representing one share of common stock. Following the award, his direct common stock holdings total 20,092 shares.

Insider Trade Summary

Grant/Award: 16,066 shares

Grant/Award 2 txns

Insider Garland Jason K

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,315	$0.00	$0.00
Grant/Award	Common Stock	7,751	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 8,315 contracts (Direct); Common Stock — 20,092 shares (Direct)

Footnotes (2)

1. F1. Mr. Garland was awarded 7,751 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. F2. One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

FAQ

What insider transactions did Repligen (RGEN) CFO Jason Garland report?

Repligen CFO Jason K. Garland reported equity awards, not open-market trades. He received 8,315 stock options and 7,751 restricted stock units as part of his compensation, both subject to multi-year vesting schedules before fully becoming available.

How many stock options did the Repligen (RGEN) CFO receive and at what price?

Jason Garland received 8,315 stock options to buy Repligen common stock at an exercise price of $141.91 per share. These options expire on March 5, 2036 and vest in three equal annual installments beginning in 2027.

What are the vesting terms of the Repligen (RGEN) CFO’s new stock options?

One third of Jason Garland’s 8,315 stock options vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. He can only exercise each portion after its respective vesting date.

How many restricted stock units did Repligen (RGEN) grant to its CFO?

Repligen granted Jason Garland 7,751 restricted stock units. Each unit represents a contingent right to receive one share of common stock, vesting in equal annual installments over three years starting on the first anniversary of the grant date.

How are the Repligen (RGEN) CFO’s restricted stock units settled?

The restricted stock units granted to Jason Garland may be settled only by delivering shares of Repligen common stock. Because they must be settled in shares, the grant is reported in the common stock table under SEC guidance.

What is the Repligen (RGEN) CFO’s direct common stock holding after this Form 4?

After the reported grants, Jason Garland directly holds 20,092 shares of Repligen common stock. This total reflects his position following the award of 7,751 restricted stock units, which will convert into shares as they vest over three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 11:51 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garland Jason K

(Last) (First) (Middle)

C/O REPLIGEN CORPORATION

41 SEYON ST., BLDG 1, STE 100

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		7,751(1)	A	$0	20,092	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$141.91	03/05/2026		A		8,315		(2)	03/05/2036	Common Stock	8,315	$0	8,315	D

Explanation of Responses:

1. Mr. Garland was awarded 7,751 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

	/s/ Jennifer Carmichael (Attorney in Fact)	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)